Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
p53 R175H A*02 TCR-T
- Development stage
- Unknown
- Lead developer
- Anocca
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anocca's p53 R175H A*02 TCR-T is an autologous, T cell receptor (TCR) engineered T cell therapy designed to target the p53 R175H hotspot mutation, which is one of the most frequent oncogenic driver mutations in the TP53 gene. The therapy utilizes high-affinity TCRs that specifically recognize the mutant p53 R175H peptide (HMTEVVRHC) presented by the HLA-A*02:01 MHC class I molecule. To optimize performance within the immunosuppressive tumor microenvironment, the T cells are engineered using non-viral gene editing and incorporate additional functional enhancements, including CD8αβ co-receptors, FAS-41BB switch receptors for improved persistence, and chimeric cytokine receptors. It is currently in Phase 1 development for the treatment of multiple solid tumors harboring the p53 R175H mutation.
- Other names
- Anocca p53 R175H TCR-Tp53 R175H HLA-A*02:01 TCR-TAnocca-p53 R175H (presented on HLA-A*02)-TCR-T cell therapy
02
Targets
TNFRSF9 (CD137 extracellular domain)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)p53 R175H/HLA-A*02:01 (Tumor protein p53 R175H mutant peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on p53 R175H A*02 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on p53 R175H A*02 TCR-T.